ULTRAGENYX PHARMACEUTICAL INC. Operating Lease, Weighted Average Discount Rate, Percent
ULTRAGENYX PHARMACEUTICAL INC. (RARE) had Operating Lease, Weighted Average Discount Rate, Percent of 10.00% as of 2025-12-31, per its 10-K filed 2026-02-18.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent · last filed 2026-02-18
- 2025-12-31: Operating Lease, Weighted Average Discount Rate, Percent 10.00%.
- 2024-12-31: Operating Lease, Weighted Average Discount Rate, Percent 10.10%.
- 2023-12-31: Operating Lease, Weighted Average Discount Rate, Percent 9.60%.
- 2022-12-31: Operating Lease, Weighted Average Discount Rate, Percent 6.70%; Operating Lease, Weighted Average Discount Rate, Percent as first filed 6.72%.
| Period end | Operating Lease, Weighted Average Discount Rate, Percent | Operating Lease, Weighted Average Discount Rate, Percent as first filed |
|---|---|---|
| 2025-12-31 | 10.00% 10-K · filed 2026-02-18 | |
| 2024-12-31 | 10.10% 10-K · filed 2026-02-18 | |
| 2023-12-31 | 9.60% 10-K · filed 2025-02-19 | |
| 2022-12-31 | 6.70% 10-K · filed 2024-02-21 | 6.72% 10-K · filed 2023-02-17 |
| 2021-12-31 | 6.64% 10-K · filed 2023-02-17 | |
| 2020-12-31 | 6.70% 10-K · filed 2021-02-12 | |
| 2019-12-31 | 7.50% 10-K · filed 2020-02-14 | |
| 2019-09-30 | 7.50% 10-Q · filed 2019-11-06 | |
| 2019-06-30 | 7.50% 10-Q · filed 2019-08-02 | |
| 2019-03-31 | 7.70% 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |